Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and Microwave Ablation in Advanced NSCLC
NCT03769129Phase 3Recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Nov 2018
- Primary completion
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Started Nov 2018; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03769129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03769129.